fbpx
close read more
News

Colorectal cancer: discover our partnership with Celsius Therapeutics in video

31/03/2022

Colorectal cancer: discover our partnership with Celsius Therapeutics in video

Servier favors open collaboration to accelerate the development of therapeutic solutions for the benefit of patients. Here is a video of our partnership with Celsius Therapeutics to advance research in oncology.

Discover our partnership with Celsius Therapeutics in video

https://www.youtube.com/watch?v=8PC-ysYOwx4

Convinced that work and ongoing dialogue between healthcare players is the best framework for rapid innovation focused on patients’ needs, Servier continues to expand and diversify its network of R&D partners.

This international and multidisciplinary network is made up of academic institutions, pharmaceutical groups and biotech companies. All of them are committed to Servier for the long term.

The partnership between Celsius Therapeutics and Servier, which began in 2020, is focused on the identification and validation of novel colorectal cancer drug targets.

Celsius Therapeutics, specialized in the discovery and development of precision medicines for patients with cancer and autoimmunity, is a leader in the application of single cell genomics.

The Group now dedicates more than 50% of
its R&D budget to the search for new cancer therapeutic solutions.

Blue March: a month to raise awareness about colorectal cancer screening

Learn more about colorectal cancer

Last news

News
29/09/2022
World Heart Day: Servier partner of the World Heart Federation campaign!
News
26/09/2022
Parkinson: Servier exercises the exclusive licensing option on collaborative program with Oncodesign Precision Medicine
News
22/09/2022
Servier collaborates in the treatment of pancreatic cancer